Stuart A Randle
CIK 1256144 · Interim President and CEO · last filed 2026-06-09
Stuart A Randle is an Interim President and CEO who has filed 86 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for TFX, was dated Jun 9, 2026. Across all open-market trades the lifetime net is −$9.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TFX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
WAYNE, PA 19087
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TFX | Interim President and CEO | 16,524 | $125.12 | $2.07M | -$6.63M | 36 | 2026-06-09 |
| QXO BUILDING PRODUCTS, INC. (BECN) Delisted | Director | 0 | $124.17 | $0 | -$3.33M | 35 | 2025-04-29 |
| Comera Life Sciences Holdings, Inc. (CMRAW) Delisted | Director | 74,116 | $0.02 | $1.4K | $41.6K | 5 | 2023-09-01 |
| Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Director | — | — | — | $0 | 4 | 2018-07-26 |
Recent Filings
86 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-09 | TFX | Mixed | +1,604 | -$526.4K | EDGAR |
| 2026-05-12 | TFX | Tax (F) | −289 | -$38.5K | EDGAR |
| 2026-01-15 | TFX | Grant (A) | +12,325 | $0 | EDGAR |
| 2025-08-07 | TFX | Buy (P) | +1,000 | $115.9K | EDGAR |
| 2025-05-13 | TFX | Grant (A) | +1,051 | $0 | EDGAR |
| 2025-04-29 | QXO BUILDING PRODUCTS, INC. (BECN) Delisted | Disp (D) | −25,970 | -$3.23M | EDGAR |
| 2024-08-16 | TFX | Notice (144) | −2,674 | -$638.9K | EDGAR |
| 2024-08-16 | TFX | Mixed | — | -$315.3K | EDGAR |
| 2024-05-28 | QXO BUILDING PRODUCTS, INC. (BECN) Delisted | Mixed | −7,500 | -$663.6K | EDGAR |
| 2024-05-23 | QXO BUILDING PRODUCTS, INC. (BECN) Delisted | Notice (144) | −7,000 | -$663.6K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.